Launch week offerEnds in00h00m00s

annual Promonthly Pro

Nevin Alex John

Has grant

Neurologist & Head of Multiple sclerosis

Monash Health

Australia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Australia

Recent Grants

Grant: Close

Pregnancy and the multiple sclerosis brain

Open Date: 2024-12-17

Close Date:

Grant: Close

Applying OCCAMS molecular razor to study the role of EBV in MS pathogenesis

Open Date: 2024-01-01

Close Date:

Grant: Open

A clinician-led feasibility, acceptability and pilot efficacy intervention to improve bone health and muscle strength in people with multiple sclerosis

Open Date: 2024-01-01

Close Date: 2027-12-01

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (36)

Ai-Lan Nguyen

University of Melbourne

AUSTRALIA

View details

Vilija Jokubaitis

MONASH UNIVERSITY

AUSTRALIA

View details

Ruth Geraldes

University of Oxford

UNITED KINGDOM

View details

Sharmilee Gnanapavan

UNITED KINGDOM

View details

Tomas Kalincik

Yale University

AUSTRALIA

View details

Yves Moreau

Full Professor

KU Leuven

BELGIUM

View details

Jonathan Stutters

University College London

UNITED KINGDOM

View details

Tarunya Arun

University of Warwick

UNITED KINGDOM

View details

James Blackstone

University College London

UNITED KINGDOM

View details

Jennifer Massey

faculty of medicine and health sciences macquarie university sydney nsw australia

AUSTRALIA

View details

Barbara Willekens

Assistant professor of neurology

University of Antwerp

BELGIUM

View details

Justin Yehuda Garber

Clinical Senior Lecturer

University of Sydney

AUSTRALIA

View details

Carolyn Young

Clinical Professor

University of Liverpool

UNITED KINGDOM

View details

Rachel A Farrell

University College London

UNITED KINGDOM

View details

Mark Slee

Flinders University

AUSTRALIA

View details

Marzena Pedrini

Senior Research Fellow

University of Western Australia

AUSTRALIA

View details

Nigel Stallard

University of Warwick

UNITED KINGDOM

View details

Claudia A.M. Gandini Wheeler-Kingshott

University College London

UNITED KINGDOM

View details

Claire Rice

Academic , Associate Professor in Neuroinflammation

University of Bristol

UNITED KINGDOM

View details

Eduardo Aguera-Morales

Profesor Asociado

Universidad de Córdoba

SPAIN

View details

Klaus Schmierer

Deputy Director of Clinical Research - Cross-institutional research leadership supporting investigator-led applied clinical research and chairing RDN funding activity

Queen Mary University of London

UNITED KINGDOM

View details

Maria José Sá

Universidade da Beira Interior Faculdade de Ciências da Saúde

PORTUGAL

View details

Yi Tian Ting

MONASH UNIVERSITY

AUSTRALIA

View details

Ingrid van der Mei

University of Tasmania

AUSTRALIA

View details

A Hawton

Associate Professor in Health Economics

University of Exeter

UNITED KINGDOM

View details

Olga Ciccarelli

Theme Director

Georgetown University School of Medicine

UNITED KINGDOM

View details

Bruce V. Taylor

AUSTRALIA

View details

norio chihara

Professor and Chair

Kobe University Hospital

JAPAN

View details

Alan Thompson

Pro Vice-Provost (London)

University College London

UNITED KINGDOM

View details

Rachael Hunter

Professor of Health Economics

University College London

UNITED KINGDOM

View details

Alessandra Lugaresi

Associate Professor

ITALY

View details

Yi Chao Foong

University of Tasmania

AUSTRALIA

View details

nikos evangelou

Clinical Professor of Neurology

University of Nottingham

UNITED KINGDOM

View details

Andrew J. Palmer

AUSTRALIA

View details

Izanne Roos

University of Melbourne

AUSTRALIA

View details

Jeannette Lechner-Scott

Hunter New England Local Health District

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nevin Alex John

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (20)

Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple Sclerosis

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial

Managing reactivation of multiple sclerosis during treatment with natalizumab

Moderate–high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.

Neurofilament heavy chain in secondary progressive multiple sclerosis

Consensus recommendations on multiple sclerosis management in Australia and New Zealand

Consensus recommendations on multiple sclerosis management in Australia and New Zealand

Executive Dysfunction and Disability in SPMS: Predictive Value of the Frontal Assessment Battery in the UCLH MS-STAT2 Cohort.

Persistent progression independent of relapse activity in multiple sclerosis

Correction: Estimation of Transition Probabilities from a Large Cohort (&gt; 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.

Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.

Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial

The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test.

Hotspots and trends in multiple sclerosis prevalence in Australia utilising disease-modifying therapy prescription data

The Potential of β-Synuclein-Specific Regulatory T Cell Therapy as a Treatment for Progressive Multiple Sclerosis

Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis

Estimation of Transition Probabilities from a Large Cohort (&gt; 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.

Collaborators (36)

Ai-Lan Nguyen

Vilija Jokubaitis

Ruth Geraldes

Sharmilee Gnanapavan

Tomas Kalincik

Yves Moreau

Jonathan Stutters

Tarunya Arun

James Blackstone

Jennifer Massey

Barbara Willekens

Justin Yehuda Garber

Carolyn Young

Rachel A Farrell

Mark Slee

Marzena Pedrini

Nigel Stallard

Claudia A.M. Gandini Wheeler-Kingshott

Claire Rice

Eduardo Aguera-Morales

Klaus Schmierer

Maria José Sá

Yi Tian Ting

Ingrid van der Mei

A Hawton

Olga Ciccarelli

Bruce V. Taylor

norio chihara

Alan Thompson

Rachael Hunter

Alessandra Lugaresi

Yi Chao Foong

nikos evangelou

Andrew J. Palmer

Izanne Roos

Jeannette Lechner-Scott

Make your next move.

Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.

Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.